Thomas E. Hughes
President and CEO at Navitor Pharmaceuticals.
Dr. Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Prior to joining Navitor, Dr. Hughes served as President and Chief Scientific Officer of Zafgen and previously led Zafgen as CEO from 2008 to 2017. During this time, Dr. Hughes established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Dr. Hughes held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Dr. Hughes currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and FaunaBio.
Visit website: http://www.navitorpharma.com/thomas-e-hughes-phd/
See also: Navitor Pharmaceuticals - Company developing medicines designed to target specific nutrient-sensing proteins to treat diseases.
Thomas E. Hughes is also referenced in the following:
Thomas E. Hughes News
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...